QR kód

High Response Rate to Carboplatin-Paclitaxel-Cetuximab and Pembrolizumab in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

The management of R/M HNSCC is rapidly evolving with new available treatment molecules and combination modalities. Anti-EGFR cetuximab (CTX) and immune checkpoint inhibitors (ICI) can be used either alone or in combination with conventional platinum-based doublet chemotherapy (with taxanes or fluoro...

Celý popis

Uloženo v:
Hlavní autoři: Bruno Chauffert, Yuedan Zhou, Liza Medjkoune, Abdenour Ouikene, Agnes Galez, Farid Belkhir, Pierre Saint-Germain, Ali Youssef, Mohamad Chehimi
Médium: Artigo
Jazyk:Inglês
Vydáno: Karger Publishers 2023-01-01
Edice:Case Reports in Oncology
Témata:
cetuximab
pembrolizumab
paclitaxel
carboplatin
head and neck squamous cell carcinoma
On-line přístup:https://www.karger.com/Article/FullText/528326
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky